Serum malondialdehyde (MDA) level as a potential biomarker of cancer progression for patients with bladder cancer

1. TORRE LA, BRAY F, SIEGEL RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87.10.3322/caac.21262Search in Google Scholar

2. SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69:7.10.3322/caac.21551Search in Google Scholar

3. FONTEYNE V., OST P., BELLMUNT J., DROZ JP., MONGIAT-ARTUS P., INMAN B., et al. Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. Eur Urol 2018; 73:40.10.1016/j.eururo.2017.03.019Search in Google Scholar

4. KASSOUF W., TRABOULSI SL., KULKARNI GS., BREAU RH., ZLOTTA A., FAIREY A., et al. CUA guidelines on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2015; 9(9–10):E690–704.10.5489/cuaj.3320Search in Google Scholar

5. VALKO M., IZAKOVIC M., MAZUR M., RHODES CJ., TELSER J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004; 266:37–565.10.1023/B:MCBI.0000049134.69131.89Search in Google Scholar

6. KONG Q., BEEL JA., LILLEHEI KO. A threshold concept for cancer therapy. Med Hypotheses. 2000; 5:529–535.10.1054/mehy.1999.0982Search in Google Scholar

7. PISOSCHI AM., POP A. The role of antioxidants in the chemistry of oxidative stress: A review. Eur J Med Chem. 2015; 97:55–74.10.1016/j.ejmech.2015.04.040Search in Google Scholar

8. GUERAUD F., ATALAY M., BRESGEN N., CIPAK A., ECKL PM., HUC L., JOUANIN I., SIEMS W., UCHIDA K. Chemistry and biochemistry of lipid peroxidation products. Free Radic Res. 2010; 44:1098–1124.10.3109/10715762.2010.498477Search in Google Scholar

9. ESTERBAUER H., SCHAUR RJ., ZOLLNER H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991; 11:81–128.10.1016/0891-5849(91)90192-6Search in Google Scholar

10. FARMER EE., DAVOINE C. Reactive electrophile species. Curr Opin Plant Biol. 200; 10 (4): 380–6.10.1016/j.pbi.2007.04.01917646124Search in Google Scholar

11. BARRERA G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol. 2012; 2012:137289.10.5402/2012/137289Search in Google Scholar

12. HONGLERTSAKUL C., OPANURAKS J., KITTIKOWIT W., BOONLA C., WUNSUWAN R., TOSUKHOWONG P. Increased urinary excretions of oxidative stress biomarkers and sialic acid associated with severity of bladder tumors. The THAI Journal of surgery. 2007; 28:133–137.Search in Google Scholar

13. BADRINATH RK., ROBERT AG. Urine based markers of urological malignancy. J Urol. 2001; 165: 600.10.1097/00005392-200102000-00081Search in Google Scholar

14. EL GENDY SM., SALAM AIM., EL-WAHAB NA., HUSSEIN MK., GABRY MS., EL-AASER AA. Urinary telomerase activity, C-erbB2, malondialdehyde and nitric oxide as biological markers of bladder cancer. Turk J Biochem. 2006; 31(4); 164–168.Search in Google Scholar

15. YALCIN O., KARATAS F., ERULAS FA., OZDEMIR E. The levels of glutathione peroxidaes, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder. Br J Uro Int. 2004; 93(6): 863–866.10.1111/j.1464-410X.2003.04729.xSearch in Google Scholar

16. KACZMAREK P., BUCZYNSKI A., NIEMIROWICZ J., GNITECKI W., KOCUR E., KARPINSKI J. Lipids peroxidation in platelets in patients with bladder cancer treated with Mycobacterium suspension. Pol Merkuriusz Lek. 2001; 11: 484–6.Search in Google Scholar

17. SAWICKA E., KRATZ EM., SZYMAŃSKA B., GUZIK A., WESOŁOWSKI A., KOWAL P., et al. Preliminary study on selected markers of oxidative stress, inflammation and angiogenesis in patients with bladder cancer. Pathol Oncol Res. 2019. doi: 10.1007/s12253-019-00620-5.10.1007/s12253-019-00620-5Search in Google Scholar

18. JELIC MD., MANDIC AD., MARICIC SM., SRDJENOVIC BU. Oxidative stress and its role in cancer. J Can Res Ther [Epub ahead of print] [cited 2019 Nov 9].Search in Google Scholar

19. GECIT I., ASLAN M., GUNES M., PIRINCCI N., ESEN R., DEMIR H., CEYLAN K. Serum prolidase activity, oxidative stres and nitric oxide levels in patients with bladder cancer. J Cancer Res Clin Oncol 2012; 138:739–743.10.1007/s00432-011-1136-4Search in Google Scholar

20. TAI WY., YANG YC., LIN HJ., HUANG CP., CHENG YL., CHEN MF., YEN HL., LIAU I. Interplay between structure and fluidity of model lipid membranes under oxidative attack. The Journal of Physical Chemistry B. 2010; 114 (47): 15642–15649.10.1021/jp1014719Search in Google Scholar

21. NIMET V., RUCKEN T. Effect of stress induced lipid peroxidation on cell function. International cell biology. 2004; 28(7):517–521.10.1016/j.cellbi.2004.04.006Search in Google Scholar

22. SEVEN A., CIVELEK S., INCI E., KORKUT N., BURÇAK G. Evaluation of oxidative stress parameters in blood of patients with laryngeal carcinoma. Clin Biochem J, 1999; 32(5): 69–73.10.1016/S0009-9120(99)00022-3Search in Google Scholar

23. BADJATIA N., SATYAM A., SINGH P., SETH A., SHARMA A. Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinoma. Urol Oncol J. 2010; 28 (4): 360–7.10.1016/j.urolonc.2008.12.01019171490Search in Google Scholar

24. DILLIOGLUGIL MO., MEKIK H., MUEZZINOGLU B., OZKAN TA., DEMIR CG., DILLIOGLUGIL O., et al. Blood and tissue nitric oxide and malondialdehyde are prognostic indicators of localized prostate cancer. Int Urol Nephrol. 2012; 44:1691–6.10.1007/s11255-012-0221-122710971Search in Google Scholar

25. KOSOVA F., TEMELTAŞ G., ARI Z., LEKILI M. Possible relations between oxidative damage and apoptosis in benign prostate hyperplasia and prostate cancer patients. Tumour Biol. 2014; 35:4295–9.10.1007/s13277-013-1560-y24375255Search in Google Scholar

26. EL-FAR M., ABOL-ENEIN H., ZAKARIA A., EL-GEDAMY M. Evaluation of nitric oxide and malondialdehyde levels in serum of Egyptian patients with bladder and renal tumors: Potential use as medicinal biomarkers. World J Pharm Pharm Sci. 2014; 3:87–101.Search in Google Scholar